5-1) reduction) Hypoglycemic risk Moderate Low Low Effect on body Gain Gain Neutral weight Common adverse Hypoglycemia Edema, HF, Adverse effects effects fractures are rare Estimated cost Low Low High DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HbAlc, glycated hemoglobin; HF, heart failure; SGLT2, sodium-glucose cotransporter-2; SU, sulfonylurea; TZD, thiazolidinedione
Whereas, GLUT4 and other specific adipocyte genes are ameliorated by thiazolidinedione
treatment (Diaz-Delfin et al.
Although a definitive link between these drugs and an increased fracture risk has not yet been proved, the evidence amassed so far is suggestive enough to prompt caution in the treatment of patients with a thiazolidinedione
It was also reported recently that the use of insulin-sensitizing thiazolidinedione
drugs, such as rosiglitazone (Avandia), which are used to treat diabetes, is associated with a two-to threefold increase in the risk of suffering an osteoporotic hip fracture.
Galvus received European Union approval in September 2007 for use in patients in combination with the anti-diabetes medicines metformin, thiazolidinedione
(TZD) or a sulphonylurea (SU).
After a review of postmarketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione
class of antidiabetic drugs.
Takeda is the originator of thiazolidinedione
derivatives and ACTOS is a member of the thiazolidinedione
class of "insulin-sensitizing" agents, and it directly targets insulin resistance.
The study reported dramatic effects, comparable to the current generation of diabetes and lipid-lowering thiazolidinedione
drugs and statins, although only an inert placebo was used as a control.
Medications of the thiazolidinedione
class traditionally used for glycemic control in patients with type 2 diabetes seem to hold promise in this respect.
A human peroxisome-proliferator-activated receptor-[gamma] is activated by inducers of adipogenesis, including thiazolidinedione
Humanized monoclonal antibodies for breast, ovarian and prostate cancer, along with thiazolidinedione
antidiabetic agents, will spur rapid growth in demand for bulk hormones and related agents.